Quarterly ResultMay 13, 2026, 07:26 AM
Xtant Medical Q1 Revenue $20.88M, Net Loss $3.09M; Divestment Proceeds Received
AI Summary
Xtant Medical reported a significant decline in Q1 2026 revenue to $20.88 million, down from $32.90 million in Q1 2025, resulting in a net loss of $3.09 million compared to a net income of $0.06 million in the prior year. The company received $8.5 million from the Companion Spine Note and $2.2 million in working capital settlement related to the Coflex/CoFix assets and international hardware business divestitures completed in December 2025. These divestitures contributed to the absence of license revenue in Q1 2026.
Key Highlights
- Received $8.5 million from Companion Spine Note and $2.2 million for Paradigm Divestiture on February 27, 2026.
- Total revenue for Q1 2026 decreased 36.5% to $20.88 million from $32.90 million in Q1 2025.
- Net loss for Q1 2026 was $3.09 million, compared to net income of $0.06 million in Q1 2025.
- Basic net loss per share was $0.02 in Q1 2026, down from $0.00 in Q1 2025.
- Orthobiologics revenue was $15.61 million (75% of total) and Spinal implant revenue was $5.28 million (25% of total).
- License revenue was $0 in Q1 2026, down from $3.62 million in Q1 2025 due to policy changes.
- Net cash used in operating activities was $2.11 million in Q1 2026, compared to $1.28 million provided in Q1 2025.
- Cash and cash equivalents decreased to $12.14 million as of March 31, 2026, from $17.05 million at December 31, 2025.
Price Impact
More from XTNT